Skip to main content
$67.51 -$0.83 (-1.2%)

12:40 PM EDT on 07/26/21

Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Current Price $67.51 Mkt Cap $152.6B
Open $68.22 P/E Ratio 0.00
Prev. Close $0.00 Div. (Yield) $1.96 (2.9%)
Daily Range $67.49 - $68.34 Volume 3,443,948
52-Wk Range $56.75 - $68.53 Avg. Daily Vol. 9,171,421


How do you think NYSE:BMY will perform against the market?

Add Stock to CAPS Watchlist

All Players

1,834 Outperform
115 Underperform

All-Star Players

297 Outperform
16 Underperform

Wall Street

0 Outperform
0 Underperform

Top NYSE:BMY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

johnclanaro (< 20)
Submitted October 28, 2013

recent upgrade. good pipeline.

msabol01 (78.68)
Submitted April 02, 2017

Strong pipeline and a culture that wants to innovate. Strong focus on patients. Leadership seems to struggle with launching products and being competitive out the door. Long term will either find BMY on strong footing or acquired.

Recent Community Commentary

Read the most recent pitches from players about BMY.


Member Avatar FoolSpec (< 20) Submitted: 5/21/2021 10:36:39 PM : Outperform Start Price: $66.75 NYSE:BMY Score: -3.87

Undervalued with a strong pipeline.


Member Avatar RES7 (82.60) Submitted: 3/8/2021 1:24:15 PM : Outperform Start Price: $60.70 NYSE:BMY Score: -1.93

Jonathon Webber SA


Member Avatar jjhegi (68.83) Submitted: 1/13/2021 11:28:51 AM : Outperform Start Price: $64.19 NYSE:BMY Score: -10.33

Cheap stock in an expensive market. Berkshire just made a large purchase late last year.


Find the members with the highest scoring picks in BMY.

No players have picked BMY yet. Tell us why you think BMY will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BMY.